MRI contrast-enhancing agents

DRUG5 trials

Sponsors

Sanofi, Shanghai Gynecologic Oncology Group, Medical University of Vienna, Université de Montréal

Conditions

DLBCL - Diffuse Large B Cell LymphomaHCC - Hepatocellular CarcinomaMultiple SclerosisOvarian Cancer (OvCa)Ovarian Cancer MetastaticSIRTTACE

Early Phase 1

ImmunoMRI for Assessment of Tumor-associated Macrophages

Not yet recruitingNCT07066436

Medical University of ViennaDLBCL - Diffuse Large B Cell Lymphoma

Start: 2025-10-31End: 2028-09-30Target: 60Updated: 2025-07-15

Phase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Active, not recruitingNCT06141473

SanofiMultiple Sclerosis

Start: 2023-12-13End: 2027-05-06Updated: 2026-05-14

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Active, not recruitingNCT06141486

SanofiMultiple Sclerosis

Start: 2023-12-27End: 2028-03-24Updated: 2026-05-14

Unknown Phase

O-RADS MRI System on Early Detection of Ovarian Cancer

Active, not recruitingNCT07009743

Shanghai Gynecologic Oncology GroupOvarian Cancer Metastatic, Ovarian Cancer (OvCa)

Start: 2025-01-01End: 2028-12-31Target: 2549Updated: 2025-06-08

OE MRI to Predict Treatment Response After TACE in HCC Patients

Enrolling by invitationNCT07617038

Université de MontréalHCC - Hepatocellular Carcinoma, SIRT, TACE

Start: 2024-11-27End: 2029-12-20Target: 60Updated: 2026-06-01

Related Papers

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials

Neurology2025-04-214 citations